Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8338143rdf:typepubmed:Citationlld:pubmed
pubmed-article:8338143lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:8338143lifeskim:mentionsumls-concept:C0026844lld:lifeskim
pubmed-article:8338143lifeskim:mentionsumls-concept:C1135918lld:lifeskim
pubmed-article:8338143lifeskim:mentionsumls-concept:C0013725lld:lifeskim
pubmed-article:8338143lifeskim:mentionsumls-concept:C0596233lld:lifeskim
pubmed-article:8338143pubmed:issue1 Pt 1lld:pubmed
pubmed-article:8338143pubmed:dateCreated1993-8-26lld:pubmed
pubmed-article:8338143pubmed:abstractTextThe role of arachidonic acid (AA) and its metabolites in vasopressin (AVP)-induced calcium mobilization in A7r5 aortic smooth muscle cells was explored by intracellular calcium monitoring, [14C]AA labeling, and high-performance liquid chromatography (HPLC) techniques. In fura 2-loaded A7r5 cells, AA potentiated AVP-stimulated increase in intracellular free Ca2+ ([Ca2+]i). The cyclooxygenase inhibitor indomethacin reduced both the AA- and AVP-induced influx of extracellular Ca2+. AVP-induced [Ca2+]i transients were not altered by lipoxygenase inhibitors but were reduced in a dose-dependent fashion by ketoconazole, an inhibitor of cytochrome P-450 monooxygenases. Among several epoxygenase metabolites of AA tested, 5,6-epoxyeicosatrienoic acid potentiated AVP-induced [Ca2+]i transients. Reverse-phase HPLC analysis of lipid extracts from A7r5 cells prelabeled with [14C]AA isolated a radioactive peak that did not coelute with established products of cyclooxygenase-, lipoxygenase-, or cytochrome P-450-catalyzed oxidations of AA. This peak was significantly increased after AVP stimulation and was completely blocked by preincubation with ketoconazole. Thus the stimulation of V1-vascular AVP receptors of A7r5 cells triggers several cytoplasmic signaling pathways involving AA metabolite formation through the cyclooxygenase and epoxygenase pathways.lld:pubmed
pubmed-article:8338143pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8338143pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8338143pubmed:languageenglld:pubmed
pubmed-article:8338143pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8338143pubmed:citationSubsetIMlld:pubmed
pubmed-article:8338143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8338143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8338143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8338143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8338143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8338143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8338143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8338143pubmed:statusMEDLINElld:pubmed
pubmed-article:8338143pubmed:monthJullld:pubmed
pubmed-article:8338143pubmed:issn0002-9513lld:pubmed
pubmed-article:8338143pubmed:authorpubmed-author:ThibonnierMMlld:pubmed
pubmed-article:8338143pubmed:authorpubmed-author:KoopD RDRlld:pubmed
pubmed-article:8338143pubmed:authorpubmed-author:SimonsonM SMSlld:pubmed
pubmed-article:8338143pubmed:authorpubmed-author:LaethemC LCLlld:pubmed
pubmed-article:8338143pubmed:authorpubmed-author:BayerA LALlld:pubmed
pubmed-article:8338143pubmed:issnTypePrintlld:pubmed
pubmed-article:8338143pubmed:volume265lld:pubmed
pubmed-article:8338143pubmed:ownerNLMlld:pubmed
pubmed-article:8338143pubmed:authorsCompleteYlld:pubmed
pubmed-article:8338143pubmed:paginationE108-14lld:pubmed
pubmed-article:8338143pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:8338143pubmed:meshHeadingpubmed-meshheading:8338143-...lld:pubmed
pubmed-article:8338143pubmed:meshHeadingpubmed-meshheading:8338143-...lld:pubmed
pubmed-article:8338143pubmed:meshHeadingpubmed-meshheading:8338143-...lld:pubmed
pubmed-article:8338143pubmed:meshHeadingpubmed-meshheading:8338143-...lld:pubmed
pubmed-article:8338143pubmed:meshHeadingpubmed-meshheading:8338143-...lld:pubmed
pubmed-article:8338143pubmed:meshHeadingpubmed-meshheading:8338143-...lld:pubmed
pubmed-article:8338143pubmed:meshHeadingpubmed-meshheading:8338143-...lld:pubmed
pubmed-article:8338143pubmed:meshHeadingpubmed-meshheading:8338143-...lld:pubmed
pubmed-article:8338143pubmed:meshHeadingpubmed-meshheading:8338143-...lld:pubmed
pubmed-article:8338143pubmed:meshHeadingpubmed-meshheading:8338143-...lld:pubmed
pubmed-article:8338143pubmed:meshHeadingpubmed-meshheading:8338143-...lld:pubmed
pubmed-article:8338143pubmed:meshHeadingpubmed-meshheading:8338143-...lld:pubmed
pubmed-article:8338143pubmed:meshHeadingpubmed-meshheading:8338143-...lld:pubmed
pubmed-article:8338143pubmed:year1993lld:pubmed
pubmed-article:8338143pubmed:articleTitleRole of eicosanoids in vasopressin-induced calcium mobilization in A7r5 vascular smooth muscle cells.lld:pubmed
pubmed-article:8338143pubmed:affiliationDepartment of Medicine, University Hospitals of Cleveland, Ohio.lld:pubmed
pubmed-article:8338143pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8338143pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed